Back
Officials

Sponsored Legislation

HJRES 105

US HOUSE

Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Land Management relating to "North Dakota Field Office Record of Decision and Approved Resource Management Plan".

119th Congress
Introduced by Julie Fedorchak,

HJRES 105 disapproves the Bureau of Land Management's North Dakota management plan, nullifying its decisions and impacting local stakeholders and land use practices.

Received in the Senate.
0
0
0
0

HR 3616

US HOUSE

Reliable Power Act

119th Congress
Introduced by Rick Allen, Troy Balderson, Gus Bilirakis and 31 other co-sponsors

The Reliable Power Act mandates annual assessments by FERC to ensure the U.S. electric grid meets demand, enhancing reliability during extreme weather and protecting consumers.

Committee Consideration and Mark-up Session Held
0
0
0
0

HR 909

US HOUSE

Crime Victims Fund Stabilization Act of 2025

119th Congress
Introduced by Alma Adams, Robert Aderholt, Mark Alford and 735 other co-sponsors

HR 909 stabilizes the Crime Victims Fund, ensuring ongoing financial support for crime victims and enhancing services like counseling and legal aid across the U.S.

Motion to place bill on Consensus Calendar filed by Mrs. Wagner.
0
0
0
0

HR 1575

US HOUSE

No American Land for Communist China Act

119th Congress
Introduced by Mark Alford, Rick Allen, Don Bacon and 156 other co-sponsors

HR 1575 prohibits entities linked to the Chinese Communist Party from acquiring U.S. land, aiming to protect national security and impact agricultural ownership dynamics.

Introduced in House
0
0
0
0

HR 1492

BILL

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

119th Congress
Introduced by Rick Allen, Mark Amodei, Troy Balderson and 51 other co-sponsors

HR 1492 extends drug price negotiations for biologics from 7 to 11 years, aiming to lower costs for consumers and reshape pricing strategies for pharmaceutical companies.

Introduced in House
0
0
0
0